2026 Ebola epidemic Singapore-based Hilleman Laboratories announces plans to advance an rVSV-based vaccine against the Bundibugyo strain of Ebola into human trials after World Health Organization experts identified it as the most promising candidate for the epidemic. Sources: AFP via CNA